m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00466)
Target Name E3 ubiquitin-protein ligase TRIM11 (TRIM11)
Synonyms
Protein BIA1; RING finger protein 92; RING-type E3 ubiquitin transferase TRIM11; Tripartite motif-containing protein 11; RNF92
    Click to Show/Hide
Gene Name TRIM11
Family TRIM/RBCC family. {ECO:0000305}.
Function
E3 ubiquitin-protein ligase that promotes the degradation of insoluble ubiquitinated proteins, including insoluble PAX6, poly-Gln repeat expanded HTT and poly-Ala repeat expanded ARX. Mediates PAX6 ubiquitination leading to proteasomal degradation, thereby modulating cortical neurogenesis. May also inhibit PAX6 transcriptional activity, possibly in part by preventing the binding of PAX6 to its consensus sequences. May contribute to the regulation of the intracellular level of HN (humanin) or HN-containing proteins through the proteasomal degradation pathway. Mediates MED15 ubiquitination leading to proteasomal degradation. May contribute to the innate restriction of retroviruses. Upon overexpression, reduces HIV-1 and murine leukemia virus infectivity, by suppressing viral gene expression. Antiviral activity depends on a functional E3 ubiquitin-protein ligase domain. May regulate TRIM5 turnover via the proteasome pathway, thus counteracting the TRIM5-mediated cross-species restriction of retroviral infection at early stages of the retroviral life cycle. {ECO:0000269|PubMed:18248090}.
    Click to Show/Hide
Gene ID 5395
Uniprot ID
TRI11_HUMAN
HGNC ID
HGNC:16281
Ensembl Gene ID
ENSG00000154370
KEGG ID
hsa:81559
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
TRIM11 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary TRIM11 regulates nasopharyngeal carcinoma drug resistance by positively modulating the Daple/beta-catenin/E3 ubiquitin-protein ligase TRIM11 (TRIM11) signaling pathway. TRIM11 enhanced the multidrug resistance in NPC by inhibiting apoptosis in vitro and promoting cisplatin (DDP) resistance in vivo. METTL3-mediated m6A modification caused the upregulation of TRIM11 via IGF2BP2 in NPC drug-resistant cells.
Target Regulation Down regulation
Responsed Disease Nasopharyngeal carcinoma ICD-11: 2B6B
 Disease Info 
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response ABC transporters hsa02010
Wnt signaling pathway hsa04310
Ubiquitin mediated proteolysis hsa04120
Cell Process Ubiquitination degradation
In-vitro Model CNE-1 Normal Homo sapiens CVCL_6888
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
In-vivo Model A total of 2 × 106 cells was mixed with 0.2 ml PBS (pH 7.4) and 30% (v/v) Matrigel matrix (BD Biosciences).
Nasopharyngeal carcinoma [ICD-11: 2B6B]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary TRIM11 regulates nasopharyngeal carcinoma drug resistance by positively modulating the Daple/beta-catenin/E3 ubiquitin-protein ligase TRIM11 (TRIM11) signaling pathway. TRIM11 enhanced the multidrug resistance in NPC by inhibiting apoptosis in vitro and promoting cisplatin (DDP) resistance in vivo. METTL3-mediated m6A modification caused the upregulation of TRIM11 via IGF2BP2 in NPC drug-resistant cells.
Responsed Disease Nasopharyngeal carcinoma [ICD-11: 2B6B]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response ABC transporters hsa02010
Wnt signaling pathway hsa04310
Ubiquitin mediated proteolysis hsa04120
Cell Process Ubiquitination degradation
In-vitro Model CNE-1 Normal Homo sapiens CVCL_6888
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
In-vivo Model A total of 2 × 106 cells was mixed with 0.2 ml PBS (pH 7.4) and 30% (v/v) Matrigel matrix (BD Biosciences).
Cisplatin [Approved]
 Drug Info 
In total 1 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary TRIM11 regulates nasopharyngeal carcinoma drug resistance by positively modulating the Daple/beta-catenin/E3 ubiquitin-protein ligase TRIM11 (TRIM11) signaling pathway. TRIM11 enhanced the multidrug resistance in NPC by inhibiting apoptosis in vitro and promoting cisplatin (DDP) resistance in vivo. METTL3-mediated m6A modification caused the upregulation of TRIM11 via IGF2BP2 in NPC drug-resistant cells.
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Down regulation
Responsed Disease Nasopharyngeal carcinoma ICD-11: 2B6B
 Disease Info 
Pathway Response ABC transporters hsa02010
Wnt signaling pathway hsa04310
Ubiquitin mediated proteolysis hsa04120
Cell Process Ubiquitination degradation
In-vitro Model CNE-1 Normal Homo sapiens CVCL_6888
CNE-2 Nasopharyngeal carcinoma Homo sapiens CVCL_6889
In-vivo Model A total of 2 × 106 cells was mixed with 0.2 ml PBS (pH 7.4) and 30% (v/v) Matrigel matrix (BD Biosciences).
References
Ref 1 TRIM11 facilitates chemoresistance in nasopharyngeal carcinoma by activating the Beta-catenin/ABCC9 axis via p62-selective autophagic degradation of Daple. Oncogenesis. 2020 May 7;9(5):45. doi: 10.1038/s41389-020-0229-9.